Korean patients and physicians still do not have access to a number of key pulmonary arterial hypertension (PAH) drugs that were approved in the U.S. and other countries almost 25 years ago, a local expert said."Multinational pharmaceutical companies (MNC) that develop pulmonary arterial hypertensio
A local cardiology expert pointed out that Korean women with acute coronary syndrome are undertreated and receive delayed treatment compared to their male counterparts, requiring a different treatment approach.Professor Kim Hyoung-oh from Kyung Hee University Medical Center stressed the importance o
Major domestic pharmaceutical firms are participating in the 38th JP Morgan Healthcare Conference that kicks off Monday, presenting their research and development (R&D) plans and global partnerships.According to several sources, Hanmi Pharmaceuticals, Yuhan, Daewoong Pharmaceutical, and LG Chem are
Nebivolol, a third-generation beta-blocker, proved its efficacy in controlling blood pressure in Korean hypertension patients.Menarini Korea announced Tuesday the results of the BENEFIT study, which is the most extensive study on Korean hypertension patients that encompassed 3,250 people.The BENEFIT
Medical school students continued to support their seniors taking the national medical examination - called the Korean Medical Licensing Examination (KMLE) - in the pouring rain.The Korea Health Personnel Licensing Examination Institute (KHPLEI) will carry out the 84th KMLE in 2020 at eight test cen
Daewoong Pharmaceutical (CEO & President Jeon Seng-ho) recently acquired rights to sell Merck’s antihypertensive drug, raising expectations of it becoming a powerhouse in the circulatory disease market.Daewoong and Merck Korea signed a domestic sales agreement for cardiovascular disease drug Concor
According to the World Health Organization, stroke is the second leading cause of death, with the global market for ischemic stroke medicines expected to reach about 2.3 trillion won this year.Against this backdrop, the domestic pharmaceutical industry is gaining momentum in researching and developi
Hugel said Monday that it would participate in the 38th JP Morgan Conference to take place next Monday, giving updates on its business at home and abroad as well as its future vision. Hugel officials will present as part of the Emerging Markets track, which introduces major Asian companies at the co
SGLT-2 inhibitors came to the forefront as one of the most controversial topics in the field of cardiology and endocrinology. Although developed as an antidiabetic drug, SGLT-2 inhibitors opened up a new era in diabetes treatment by demonstrating cardiovascular benefits while proving its potential a
The new year is here, bringing with it hopes of a new life. While many celebrate the new year with festivities, a specialized medical team hold their ground at a regional trauma center where they battle to save patients’ lives. This special task force utilizes every minute and second to treat patien
Although cardiac rehabilitation proved its effectiveness in preventing and treating heart disease through numerous studies, awareness of such a program remains low among Korean patients, doctors, and the government itself."Cardiac rehabilitation is an excellent treatment for heart disease patients,
The Ministry of Food and Drug Safety approved 23 new drugs in 2019, many of which are anticancer and rare disease therapies. Four therapies gained reimbursement while the rest are waiting for insurance approval from the drug regulator. The Medical Observer took a look at the therapies approved last
Experts are speculating whether Korean firms will successfully develop non-alcoholic steatohepatitis (NASH) drugs, considering multinational pharmaceuticals are discontinuing development.Boehringer Ingelheim and Gilead Sciences have run into roadblocks developing NASH drugs. At the same time, Korean
Baseball players and clinical trials have a lot in common. A baseball player swings numerous times to hit the ball but misses many times before hitting it out the field or scoring a home run. Clinical trials are no different. For an investigational compound to become a drug, it has to go through var